What is Tardive Dyskinesia?

1. About Tardive Dyskinesia Disease Understanding and Treatment Algorithm Tardive Dyskinesia market report A number of challenges with Tardive Dyskinesia remain, including the ability to quantify the risk of TD caused by pharmacologic management, the difficulty of diagnosing TD even with The Dyskinesia Identification System Condensed User Scale (DISCUS) and other approaches, the exposure of older patients to both typical and atypical APDs, and the dyskinesia caused by other neurologic disorders. Additionally, the unclear pathophysiology of TD continues to be a problem for the successful treatment and management of the condition. TD is commonly misdiagnosed as mental illness rather than neurologic dysfunction, resulting in the prescription of APDs that can further worsen

2. the condition. Definitive classification of TD is necessary to prevent such treatment problems from occurring. New medications have been developed for TD, but may be too expensive for many patients. It can be observed that the prevalent cases of Tardive Dyskinesia market is expected to increase in the 7MM during the forecast year, with an improvement in treatment pattern as well. Treatment of TD is highly individualized. Since, TD is caused by dopamine blockage, initial treatment includes gradual removal of the dopamine blocking agents. Many times, these agents cannot be removed, as these agents are used for a variety of illnesses (such as gastrointestinal and psychiatric). The doctor may switch the patient to a different antipsychotic that may lessen TD. Many available treatments for TD offer some benefit to patients, but response to treatment depends on the patient. Ingrezza (valbenazine) and Austedo (deutetrabenazine) are two FDA approved drugs used for treatment of TD. Tetrabenazine is often useful for symptomatic treatment of TD and is currently available for use in the US. However, it carries the risk of causing or aggravating depression. Other experimental drugs are being tested to reduce or eliminate the symptoms of tardive dyskinesia. The Tardive Dyskinesia pipeline is very narrow which reflects that there is a high medical unmet need for potential treatment options for the patients. The dynamics of TD market is anticipated to change in the coming years owing to the improvement in the research and development activities so that market will comprise of efficient treatment regimens. Source: - Tardive Dyskinesia Market Report